The Paper's reporter Ge Jia
Although the pharmaceutical sector continued to perform sluggishly in the third quarter, the scale of the "medicine-based goddess" CEIBS fund Gülen's products in management further approached 100 billion.
On October 27, Gülen's products under management all disclosed the third quarterly report, as of the end of the third quarter, its scale of public funds under management further increased to 97.001 billion yuan, an increase of 12.1 billion yuan in a single quarter, an increase of 14.31%.
This situation is completely different from the other two "100 billion top stream" fund managers, Zhang Kun of E Fund and Liu Yanchun of Invesco Great Wall Fund.
In addition, according to the third quarterly report, Gülen has taken over two private asset management plans since May 2021, with a scale of more than 1.2 billion yuan at the end of the period. In other words, Gülen's total assets under management exceeded RMB98.2 billion at the end of the third quarter.
Gülen, who has an amazing "gold-sucking" physique, is a pity in the three quarterly reports of 2 pharmaceutical funds - CEIBS Medical Health and CEIBS Medical Innovation, only to say: The overall operation of high positions has been maintained, and it has focused on the layout in the direction of long-term optimistic innovative drug industry chain, medical services, and leading enterprises of high-quality generic drugs.
From the perspective of position changes, compared with more than 90% of the stock positions at the end of the second quarter, the stock positions of CEIBS Medical Health and CEIBS Medical Innovation at the end of the third quarter both fell, falling by 3.81%, 4.72%, to 89.62% and 86.65% respectively in a single quarter.
Specific to the changes in heavy stocks, the top ten heavy stocks in CEIBS Healthcare are: WuXi AppTec (603259. SH), Aier Ophthalmology (300015. SZ), 002821. SZ), Tigermed (300347. SZ), Kang Longhuacheng (300759. SZ), Tongce Medical (600763. SH), Boteng Shares (300363. SZ), Zhifei Bio (300122. SZ), Mindray Medical (300760. SZ), Medici (688202. SH）。 Except for the single quarterly holdings of Boten shares, which have not changed, and Medici has been slightly reduced by Gülen, the remaining 8 heavy stocks have been increased by fund managers.
CeIBS Healthcare's top ten heavy stocks in the third quarter, source: Wind
The top ten heavy stocks of CEIBS Medical Innovation at the end of the third quarter are highly overlapping with CEIBS Medical Health, only excluding Zhifei Bio and Mindray Medical and adding WuXi Biologics (02269. HK) and Kyushu Pharmaceutical (603456.SH).
CeIBS Medical Innovation's top ten heavy stocks in the third quarter, source: Wind
In addition, Gülen also manages three partial stock hybrid funds, cerebellum new starting point and CEIBS Alpha are managed by it alone, and the newly established CEIBS Research Select on March 24 this year is jointly managed by Gülen and Lu Chunqing, deputy general manager of CEIBS Fund.
In terms of overall positions, the stock positions of the above three funds at the end of the third quarter have increased, and the latest positions of CEIBS Mingrui and CEIBS Alpha are 93.97% and 94.28% respectively; CEIBS Research Select also opened a position rapidly in the third quarter, from 37.01% at the end of the second quarter to 58.36% at the end of the third quarter.
In terms of heavy stocks, CEIBS Alpha reduced its holdings in the third quarter of CATL (300750. SZ), WuXi AppTec, Aier Ophthalmology, Ewell Lithium Energy (300014. SZ), Gloria Ying; The new starting point of Cervix Mingrui has reduced its holdings in NINGDE Era, Ewell Lithium Energy, and WuXi AppTec.
Central European Alpha three quarterly reports the top ten heavy stocks, source: Wind
In addition, CEIBS Alpha increased its stake in LONGi in the third quarter (601012. SH), Gifted Materials (002709. SZ), Shanxi Fenjiu (600809. SH), Enjie Shares (002812. SZ), Sunshine Power (300274. SZ); Cervix Mingrui new starting point increased its holdings in Tianci Materials, LONGi Shares, Sungrow Power, Enjie Shares, Ganfeng Lithium (002460. SZ), North Huachuang (002371. SZ), Kelley Young.
Cervix Mingrui New Start Three Quarterly Report Top Ten Heavy Stocks, Source: Wind
In addition to Sunshine Power, LONGi Shares, Shanxi Fenjiu, WuXi AppTec, Aier Ophthalmology, oriental wealth (300059. SZ), Tongwei shares (600438. SH), Tencent Holdings (00700. HK), Li Ning (02331. HK), FuHanwei (300613. SZ) figure.
CEIBS Research selected the top ten heavy stocks in the third quarter report, source: Wind
Gülen reiterated her views in the third quarterly report of Celebrant Alpha: the fund has long been positioned to focus on high-quality companies with competitive barriers, mainly in three directions: 1. mandatory consumer goods, immunity to macroeconomic and peripheral shock disturbances, such as medicine and some food and beverages; 2, select consumer goods and service industries, the industry pattern is good, leading companies with pricing power; 3, in the field of scientific and technological innovation, looking for companies with international competitiveness and even occupying a place in the global industrial chain.
"We are still optimistic about this round of scientific and technological innovation cycle in the medium and long term, and profound changes will occur in the medium and long term in the corresponding fields of industry in China." We divide the risk into two categories: permanent loss and temporary adjustment, and we believe that the core of risk control is to avoid permanent losses as much as possible, which requires us to carefully select enterprises and adhere to the best quality companies. Gülen wrote.
Looking back at the stock market's long bull stocks and reviewing the test of the market's sharp adjustment in investment in the past few years, Gülen believes that through in-depth fundamental research, focusing on core high-quality growth stocks and avoiding permanent losses is an effective strategy for long-term performance. She believes that the current layout of the track and the individual stocks held still have huge room for growth in the future, and the performance continues to have strong upward momentum.
Editor-in-Charge: Wang Jie